earnings

Dollar heads for small weekly loss on Middle East peace deal expectations Reuters

Robust first-quarter corporate results, driven by technology megacaps, have provided fundamental support to the stock-market rally, dimming worries about elevated Treasury yields, according to HSBC Bank Plc’s Max Kettner.

Uipath expects FY2027 revenue $1.776B-$1.781B while raising non-GAAP operating income outlook to ~$430M

Dollar heads for small weekly loss on Middle East ceasefire deal expectations Reuters

Ashok Leyland's shares dipped 2% despite a 14% YoY rise in net profit to Rs 1,291 crore for Q4 FY26. Revenue grew over 17% to Rs 17,246 crore. Analysts remain cautious, citing diesel price hikes and commodity inflation as headwinds, with mixed target price adjustments.

Critics say measure risks undermining electoral process and creating new avenues for contesting results.

CLSA sees nearly 60% upside in Ather Energy, initiating coverage with an “Outperform” rating and a Rs 1,450 target. The brokerage cites a “twin engine” of cost deflation and premiumisation, strong software-led revenues, and improving unit economics, expecting EBITDA breakeven by FY28 and significant

Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically en

Japan Economic Snapshot: Data beats estimates across retail, output, and jobs as Tokyo inflation cools

Supriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surging 50%. Robust demand across therapeutic segments, improved capacity utilisation, and traction in regulated markets supported growth. The stock remains in an uptr